Clinical Trials Logo

Filter by:
NCT ID: NCT05604144 Active, not recruiting - Pain Management Clinical Trials

Cryoanalgesia for the Treatment of Pain in Subjects With Morton's Neuroma

Start date: August 22, 2022
Phase: N/A
Study type: Interventional

This is a Proof-of-Concept Trial to define the safety, efficacy and feasibility of a cryoanalgesic device (iovera°®) for the treatment of pain in subjects diagnosed with Morton's Neuroma, who have failed conservative therapies.

NCT ID: NCT05604040 Active, not recruiting - Hypertension Clinical Trials

Home Blood Pressure Monitoring to Improve Hypertension

Start date: October 14, 2022
Phase: N/A
Study type: Interventional

The goal of this single group pre-post-study is to test the possibility of self-monitoring with shared medical appointments program for lifestyle education in improving blood pressure (BP) of patients with uncontrolled hypertension. The main questions it aims to address is: 1. To assess if patients with uncontrolled hypertension and their physicians will be interested in trying a program that includes self-monitoring with 6-week support for lifestyle changes and coping skills to improve BP and hypertension control. 2. To assess if patients with uncontrolled hypertension can safely participate in a program that includes self-monitoring with 6-week support for lifestyle changes and coping skills to improve their BP and ability to self-manage hypertension Participants will: - Send self-reports of their home BPs, diet, physical activity and emotions - Attend 6-week education program of lifestyle changes and coping skills delivered by physicians, holistic psychotherapists and yoga therapists.

NCT ID: NCT05603832 Active, not recruiting - Post Operative Pain Clinical Trials

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

Start date: November 17, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.

NCT ID: NCT05603312 Active, not recruiting - Parkinson Disease Clinical Trials

A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

Start date: October 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this clinical trial is to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease.

NCT ID: NCT05601882 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Level Up
Start date: November 28, 2022
Phase: Phase 3
Study type: Interventional

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment period 1 and a 16-week treatment period 2. During period 1, participants are randomly assigned in 1 of 2 groups, called treatment arms to receive upadacitinib Dose A or dupilumab. In Period 2, participants will receive upadacitinib Dose A or Dose B. Approximately 880 adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 330 sites worldwide. Participants will receive upadacitinib oral tablets once daily or dupilumab as per its label for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT05601804 Active, not recruiting - Obesity Clinical Trials

TARGETing Healthy Weight Loss in the Context of Food Insecurity

TARGET P&F I
Start date: September 1, 2022
Phase:
Study type: Observational

This pilot and feasibility study will collect information from food insecure, as well as food secure, women with obesity to detail their desires and needs for healthy weight reduction. Up to 60 women with obesity will be enrolled. Pennington Biomedical Research Center will coordinate this qualitative study and use focus groups discussion to collect formative data.

NCT ID: NCT05601362 Active, not recruiting - Depression Clinical Trials

Evaluation of a Therapeutic Mobile App for Depression

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is a preliminary evaluation of a gamified attention bias modification training (GAMBT) for reducing symptoms of depression and rumination. Individuals with elevated symptoms of depression will use the digital intervention over the course of 4 weeks. They will complete a brief (~5 question) survey daily, as well as weekly assessments.

NCT ID: NCT05601128 Active, not recruiting - HIV Infections Clinical Trials

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

CAPRI
Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.

NCT ID: NCT05600348 Active, not recruiting - Healthy Clinical Trials

Dose-dependent Identification of Unique Biomarkers

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the research is to assess the dose-dependent impacts of the consumption of fresh pork on blood-borne metabolites (markers) following the controlled feeding of pork

NCT ID: NCT05600114 Active, not recruiting - Clinical trials for Social Anxiety Disorder

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Start date: October 27, 2022
Phase: Phase 2
Study type: Interventional

A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).